China approves sale of Fibrogen China to Astrazeneca – Eurasia Business News

China approves sale of Fibrogen China to Astrazeneca – Eurasia Business News

By John Miller, consultant in pharma market – Eurasia Business News, August 18, 2025. Article no. 1722 China has officially approved the sale of FibroGen China to AstraZeneca. The transaction, initially announced in early 2025, involves AstraZeneca acquiring FibroGen’s China unit for approximately $160 million to gain regional rights to the oral anemia drug roxadustat…

Read More
Standard Chartered seizes stablecoin opportunity in Hong Kong

Standard Chartered seizes stablecoin opportunity in Hong Kong

Standard Chartered has entered Hong Kong (China SAR)’s stablecoin sector as the SAR passes a law—the Stablecoins Ordinance—allowing licensed businesses to issue fiat-referenced tokens. Initially, only a limited number of licenses will be offered, providing Standard Chartered with an opportunity to capitalise on strong demand for crypto and shape client-facing infrastructure, pricing, and standards as…

Read More